In order to develop our complex, breakthrough technology, we recruited some of the country’s leading scientists in acoustic engineering, plasma physics and immunology who have supported the US Space Program, the nuclear fusion industry and even cancer research. Our technology has also been enabled by design partnerships with GE and Sanmina (the world’s largest medical device manufacturer) and supported by our shareholders, including leading research centers.
We’re committed to holding our technology and its applications to the highest scientific standards, including ongoing clinical trials for current and future applications. We also believe in education and transparency, and as you’ll see in our trials section, we explain what makes up a comprehensive clinical trial, and showcase our data. We continue to conduct clinical trials for tattoo removal and we are expanding our clinical trial activities to include cellulite and other aesthetic indications.
Explore our technology and roadmap:
Walter V. Klemp – Co-Founder and Executive Chairman Wally Klemp is an experienced and successful entrepreneur with 30 years of company-building history. He has founded multiple Houston-based biotech companies collaborating with MD Anderson Cancer Center, including Moleculin Biotech, Inc, which he took public in 2016 . He has focused the last 15 years on developing and marketing therapeutic devices and drugs from concept through FDA approval. Prior to that, Mr. Klemp was founder, CEO and Chairman of Drypers Corporation, a publicly traded multinational consumer products company, growing Drypers from start-up to nearly $500 million in annualized sales and #1 on the INC 500 List of America’s Fastest Growing Companies, and earning the American Marketing Association’s Gold Edison Award. He developed growth strategies, orchestrated mergers and acquisitions, and had direct responsibility for nearly $.75 billion in public and private financings.
Christopher Capelli, M.D. – Co-Founder, President and CSO, Director Dr. Capelli is the lead inventor of Soliton’s RAP technology. Chris led the Office of Technology Based Ventures at The University of Texas M.D. Anderson Cancer Center where he formed the foundational concepts that have become RAP and eventually left MD Anderson to co-found Soliton. Prior to MD Anderson, Dr. Capelli served the director of the Office of Technology Management at the University of Pittsburgh. Both an MIT engineer and a medical doctor, Chris is the inventor of numerous patents. He was the founder of BioInterface Technologies, Inc., which developed new a silver-based antimicrobial technology for use in wound care, and he was co-inventor of the core technology that eventually became Dexcom, an $8 billion medical device company.
Lori Bisson – Chief Financial Officer Prior to joining Soliton, Ms. Bisson worked as a financial and business development consultant advising a number of life science companies. Lori served as the CFO of Zeno Corporation, a medical device company focused on new technology in the aesthetics area, and previously held various positions with Drypers Corporation, a publicly traded multinational consumer products company, where she ultimately held the title of Vice President of Integrated Solutions and oversaw accounting, information technology, and logistics for the US operation. Lori began her career at Arthur Andersen, LLP as an auditor focused on consumer products companies.
Joe Tanner – Chief Operating Officer In addition to being a lawyer and having served as a Washington State Senator, Mr. Tanner has served as Chief Operating Officer of Zeno Corporation, a company that developed and marketed dermatology devices and drugs from concept through FDA approval and market launch. Prior to that, Joe has held senior leadership positions in the contract electronics manufacturing industry as well as the consumer products industry, with responsibilities for both domestic and international operations.
Science Advisory Board
* Members of the CoolSculpting (Zeltiq) Medical Advisory Board
Brad Hauser: Mr. Hauser joined our Board of Directors effective as of June 15, 2018. He has served as the Vice President, R&D and General Manager for CoolSculpting at Allergan Pharmaceuticals since ZELTIQ Aesthetics, Inc. was acquired by Allergan in April 2017. Previously, he served as the Senior Vice President of Research and Development at ZELTIQ Aesthetics, Inc. from January 2017 to April 2017 and as its Vice President of Research and Development from July 2015 to January 2017. Mr. Hauser joined ZELTIQ in December 2013 as Vice President of Product and Clinical Strategy. Prior to joining ZELTIQ, he held multiple roles in the aesthetic industry, including Executive Vice President of Commercial Operations for Cutera, Director of Research and Development at Medicis and Managing Director of Product and Clinical Marketing at Solta Medical. Mr. Hauser received his Bachelor of Arts in Human Biology from Stanford University.
Danika Harrison: Ms. Harrison has been the President and CEO of Elira Therapeutics, Inc. since September 2017. Prior to that she served as Senior Vice President of Global Marketing at ZELTIQ Aesthetics, Inc. from January 2017, serving as its Vice President of Global Marketing from February 2016 and as VP of Consumer and Brand Marketing from November 2014. Ms. Harrison served as Senior Vice President of Direct Marketing & Innovation at TRIA Beauty, Inc. from December 2013 to June 2014, serving previously as Senior Vice President of Global Marketing from December 2011, and as VP/GM of North America from March 2011. From April 2006 to March 2011, Ms. Harrison worked at Rosetta, a consulting-centered interactive agency, where she was most recently a Partner leading the relationship marketing group consulting for leading brands like Dannon, Johnson’s Baby and Rogers to develop direct and digital marketing programs throughout the United States and Canada. Ms. Harrison holds a B.S. from Georgetown University and an M.B.A. from the Kellogg School of Management at Northwestern University.
Jonathan Foster: Mr. Foster currently serves as the Chief Financial Officer for Moleculin Biotech, Inc. (MBI), a drug development company traded on the Nasdaq Exchange developing novel cancer therapies. Prior to his tenure at MBI, Mr. Foster served as the CFO of InfuSystem Holdings, Inc., a medical technology company producing pumps for hospital use, from 2012 to 2016. Prior to InfuSystem, Mr. Foster served as a consultant to the Chief Financial Officer of LSG Sky Chefs, USA, Inc., a subsidiary of Deutsche Lufthansa AG. Prior to that, from 2000-2012, he was President, CFO and majority owner of United Credit, Inc. & Advance Today, Inc., a privately-owned consumer finance company with multiple locations. From 1996-2000, Mr. Foster served as Executive Vice President and Chief Financial Officer of Drypers Corporation. He previously served as Chief Financial Officer of Dickson Weatherproof Nail Company, Controller & Treasurer of divisions of Schlumberger Industries, and as a Manager in the Middle Market Group of Deloitte & Touche. He has also served on the State of South Carolina Board of Financial Institutions and the Board of Directors for the Easley Baptist Hospital Foundation. Mr. Foster has a BS in Accounting from Clemson University, is a Certified Public Accountant and AICPA Chartered Global Management Accountant.